
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Excipients Step into the Spotlight
over 16 years ago
Anniversary Seasonover 16 years ago
Outsourcing Clinical Trial Development and Materialsover 16 years ago
Leveling the Compliance Playing Fieldover 16 years ago
Excipients Step into the Spotlightover 16 years ago
EU Debt Crisis Adds Uncertaintyover 16 years ago
Puerto Rico Builds a Foundation for Biopharmaceuticalsover 16 years ago
Even Packaging Can Multitaskover 16 years ago
Securing the Supply Chainover 16 years ago
A Q&A with Uwe Ross of Binderover 16 years ago
Making a Difference





